Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform. pTau is recognized as an important fluid biomarker linked to the diagnosis of Alzheimer’s disease (AD). The ADDF Diagnostics Accelerator initiative is part of a collaboration with Gates Ventures and other philanthropic partners.
Blood-based testing could have the potential to become a simple, accessible, and scalable approach to help support the diagnosis of AD. Of all the AD blood biomarkers under investigation, pTau has particular promise1. Access to a fully automated Lumipulse® G plasma pTau181 assay will allow clinicians and clinical research professionals to measure plasma pTau181 levels with a high degree of precision and efficiency. The test could also help simplify AD drug clinical trial recruitment of eligible cohorts.
“We are pleased to begin this cooperation with the ADDF, cementing the active engagement of Fujirebio to reach new milestones in AD testing,” said Christiaan De Wilde, CEO of Fujirebio Europe. “Fujirebio has an unrivalled heritage as a pioneer in the field of AD research, and the desire to tackle this and other neurodegenerative diseases runs deep throughout our teams. The possibility of easily accessible blood tests for the fully automated diagnosis of AD is a breakthrough the world is eagerly waiting for.”
Fujirebio was the first company to develop and market cerebrospinal fluid (CSF) biomarkers under the Innogenetics brand over 25 years ago. Today these products are an essential part of routine AD testing in many parts of the world. Fujirebio remains the only company with such a comprehensive line-up of fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.
About Fujirebio
Fujirebio is a global leader in the field of in vitro diagnostics (IVD) testing with more than 50 years’ experience in the conception, development, production and worldwide commercialization of robust IVD products. These span the range from specialized testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
About the Diagnostics Accelerator
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator is a collaborative research initiative funded by leading philanthropists including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, and The Association for Frontotemporal Degeneration among others to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
References
1. Zetterberg & Blennow, Mol Neurodegener 2021; 16 :10.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005491/en/
Contact information
For media:
Christiaan De Wilde
CEO Fujirebio Europe
+32-9329-1703
Public Relations Section, Public Relations/Sustainability Dept.
+81-3-6279-0884
pr@hugp.com
For investors and analysts:
IR/SR Dept.
+81-3-5909-3337
ir@hugp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands the MasterFrame Series with the Compact and Modular MasterFrame 400 Mesh12.11.2025 14:07:00 EET | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the MasterFrame 400 Mesh, a compact PC case that brings the signature MasterFrame design language to a more accessible, desk-friendly format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112507322/en/ MasterFrame 400 Mesh shown with V4 3DHP air cooler. The MasterFrame 400 Mesh delivers FreeForm 2.0 modularity in a simplified build experience. It offers dual orientation for vertical or horizontal setups, repositionable brackets, and mesh-optimized airflow so builders can tailor layout and thermals with confidence. The result is a compact footprint that still supports serious hardware. The case is engineered for Micro-ATX and Mini-ITX systems and supports high-performance components without compromise. Builders can install GPUs up to 390 mm and air coolers up to 190 mm. Cooling headroom is extensive, with support for up to nine f
IonQ to Highlight Real-World Quantum Applications at Web Summit 202512.11.2025 14:05:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in Web Summit 2025, one of the largest technology events in Europe. IonQ’s President of Quantum Computing and co-founder of Oxford Ionics, Dr. Chris Ballance, is scheduled to speak during the conference’s AI Summit on Thursday, November 13, 2025, at 10:30 AM local time. The AI Summit session, “Quantum Without Compromise: The Race to Real-world Applications,” will be moderated by technology journalist, Mary-Ann Russon. The discussion will focus on IonQ’s recent breakthroughs in quantum gate fidelity and how these advancements underpin the company’s roadmap toward fault-tolerant systems. Dr. Ballance will also share how these engineering accomplishments translate into quantum computing’s growing impact across industries. “We’re at a pivotal moment where breakthroughs in quantum performance can unlock new opportunities, including real-world applications across industries like financial services, manu
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD12.11.2025 14:04:00 EET | Press release
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understanding (MOU) with Benta SAS. The MOU expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112416172/en/ PTSD is a chronic and debilitating condition that affects millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, there has been no new approved drug for PTSD in over two decades — underscoring a critical unmet medical need. As part of its clinical development pipeline, Ananda Scientific is currently advancing Nantheia
Global Airline Reliability Improves in October, Led by Asia-Pacific as North America Faces Operational Pressures; Cirium Analysis12.11.2025 14:00:00 EET | Press release
Cirium, the world’s most trusted source of aviation analytics, has published its October 2025 On-Time Performance (OTP) Report, covering more than 370,000 flights with 99.8% global coverage. The data indicates a 26% reduction in global cancellations compared with September, reflecting improved operational stability across the commercial aviation network. The results also highlight distinct regional dynamics shaping airline performance worldwide. Asia-Pacific carriers led the recovery, cutting flight cancellations by 43% as airlines across Japan, South Korea, and the Philippines strengthened network performance and capacity. Notably, the world’s top-performing airports in October — Harbin Taiping and Changchun Longjia in China, and Kaohsiung International in Taiwan — were all located in the region, underscoring its continued operational gains and steady recovery momentum. North American operations showed greater operational strain, with flight cancellations rising by about 12.6% month o
New Study Further Validates Environmental Benefits of Floor Refinishing Compared to Replacement12.11.2025 13:00:00 EET | Press release
A recent report and lifecycle assessment (LCA) conducted by IVL Swedish Environmental Research Institute confirms refinishing hard flooring surfaces, including wood, vinyl and linoleum, is more sustainable for the environment than replacing the flooring surfaces. This new study, which was conducted for the German market, is the next step of research inspired from a previous 2019 study conducted in Sweden. Both studies aim to evaluate the environmental impact of replacing a worn, damaged or outdated flooring surface compared to refinishing the flooring surface which may include sanding, finishing, staining, or painting. Bona, a global, family-owned company that supplies products for installing, renovating, maintaining, and restoring premium floors, commissioned this new study to build on the findings from a 2019 Swedish study. The new research focused on Germany, a market with a population eight times larger than Sweden, and analysed a 20 square metre scenario, reflecting a smaller, dom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom